Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea‐predominant IBS
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Summary: Background: Patients with irritable bowel syndrome with diarrhoea ( IBS ‐ D ) experience restriction in daily activities and decreased health‐related quality of life ( QOL ). Aim: To investigate effects of alosetron on patient‐reported health‐related QOL , satisfaction and productivity in women with severe IBS ‐ D . Methods: A total of 705 women (severe IBS ‐ D , Rome II criteria) randomised to alosetron 0.5 mg QD , 1 mg QD , 1 mg BID , or placebo for 12 weeks were studied. IBSQOL , treatment satisfaction, daily activities, and lost workplace productivity ( LWP ) were evaluated at randomisation and Week 12. Results: One or more doses of alosetron significantly improved all IBSQOL domains except for sexual function from baseline vs. placebo. The magnitude of IBSQOL changes was consistent with a clinically meaningful effect. Alosetron 0.5 mg QD and 1 mg BID significantly reduced IBS interference with social/leisure activities and LWP from baseline vs. placebo [social/leisure (mean ± S.E. ) days lost: −6.7 ± 0.8, −7.0 ± 0.9, P < 0.01; LWP (mean ± S.E. ) h lost: −11.0 ± 3.3, −21.1 ± 4.1, P < 0.05 respectively]. Significantly more patients treated with alosetron reported satisfaction vs. placebo. Improvements in IBSQOL , LWP , and treatment satisfaction significantly correlated with global improvement of IBS symptoms. The incidence of adverse events with alosetron was low with constipation being the most commonly reported event. A single case of ischaemic colitis occurred, in a patient receiving alosetron 0.5 mg QD . Conclusions: In women with severe IBS ‐ D , alosetron treatment, including 0.5 mg QD , resulted in statistically significant and clinically relevant improvements in health‐related QOL , restriction of daily activities and treatment satisfaction over placebo. IBS symptom improvement corresponded with positive changes in IBSQOL , LWP and treatment satisfaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Self-citationThe impact of irritable bowel syndrome on health-related quality of life
Gralnek, I. M., Hays, R. D., Kilbourne, A., Naliboff, B., & Mayer, E. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.16484 · Cited by 781 · cited 2×
“Discontinued n = 60 (34%) Adverse event (20) Consent withdrawn (16) Protocol violation (10) Lost to follow-up (3) Other (11) Discontinued n = 65 (37%) Adverse event (12) Consent withdrawn (19) Protocol violation (16) Lost to follow-up (7) Other (11)”
BackgroundFord, A. C., Brandt, L. J., Young, C., Chey, W. D., Foxx-Orenstein, A. E., & Moayyedi, P. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.223 · Cited by 261
Irritable bowel syndrome and surgery: A multivariable analysis☆
Longstreth, G. F., & Yao, J. F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.020 · Cited by 248
Efficacy of alosetron in irritable bowel syndrome: a meta‐analysis of randomized controlled trials
Cremonini, F., Delgado‐Aros, S., & Camilleri, M. (2003) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2003.00389.x · Cited by 219 · cited 2×
“Discontinued n = 60 (34%) Adverse event (20) Consent withdrawn (16) Protocol violation (10) Lost to follow-up (3) Other (11) Discontinued n = 65 (37%) Adverse event (12) Consent withdrawn (19) Protocol violation (16) Lost to follow-up (7) Other (11)”
BackgroundSelf-citationThe economic impact of irritable bowel syndrome
Inadomi, J. M., Fennerty, M. B., & Bjorkman, D. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.t01-1-01736.x · Cited by 190 · cited 1×
“9 Ethnic origin [n (%)] Caucasian 154 (88) 163 (92) 158 (90) 145 (87) Black 10 (6) 8 (5) 5 (3) 10 (6) Hispanic 10 (6) 6 (3) 10 (6) 12 (7) Others 2 (1) (0) 2 (1) (0) Quality of Life Scores (Mean ± S.”
Lackner, J. M., Jaccard, J., Krasner, S. S., Katz, L. A., Gudleski, G. D., & Holroyd, K. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.004 · Cited by 176
Occurrence of Colon Ischemia in Relation to Irritable Bowel Syndrome
Cole, J. A., Cook, S. F., Sands, B. E., Ajene, A. N., Miller, D. P., & Walker, A. M. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04097.x · Cited by 121
Cited by
A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
Garsed, K., Chernova, J., Hastings, M., Lam, C., Marciani, L., Singh, G., Henry, A., Hall, I., Whorwell, P., & Spiller, R. (2014) · Gut · doi:10.1136/gutjnl-2013-305989 · Cited by 246
Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem
Frändemark, Å., Törnblom, H., Jakobsson, S., & Simrén, M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0262-x · Cited by 209
The Impact of Revascularisation on Quality of Life in Chronic Mesenteric Ischemia
Blauw, J. T. M., Pastoors, H. A. M., Brusse-Keizer, M., Beuk, R. J., Kolkman, J. J., Geelkerken, R. H., & for the Dutch Mesenteric Ischemia Study Group (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/7346013 · Cited by 18
Metadata
- Authors
- Cremonini, F., Nicandro, J. P., Atkinson, V., Shringarpure, R., Chuang, E., & Lembo, A.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2012-07-10
- Volume
- 36
- Issue
- 5
- Pages
- 437-448
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2043222610
- Cited by
- 64
- References
- 9
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea‐predominant IBS. https://app.cochat.ai/papers/10.1111/j.1365-2036.2012.05208.x
- The paper
- Cremonini, F., Nicandro, J. P., Atkinson, V., Shringarpure, R., Chuang, E., & Lembo, A. (2012). Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea‐predominant IBS. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2012.05208.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.